People: ProPhase Labs Inc (PRPH.W)
PRPH.W on CBOE When Trading NASDAQ Global Select Market
1.62USD
27 Feb 2013
1.62USD
27 Feb 2013
Price Change (% chg)
$-0.51 (-23.94%)
$-0.51 (-23.94%)
Prev Close
$2.13
$2.13
Open
$1.62
$1.62
Day's High
$1.62
$1.62
Day's Low
$1.62
$1.62
Volume
300
300
Avg. Vol
121
121
52-wk High
$2.13
$2.13
52-wk Low
$0.99
$0.99
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Ted Karkus |
52 | 2009 | Chairman of the Board, Chief Executive Officer |
Robert Cuddihy |
52 | 2011 | Chief Financial Officer, Chief Operating Officer, Executive Vice President |
Mark Burnett |
52 | 2009 | Independent Director |
Mark Frank |
50 | 2009 | Independent Director |
Louis Gleckel |
56 | 2009 | Independent Director |
Mark Leventhal |
63 | 2009 | Independent Director |
James McCubbin |
48 | 2009 | Independent Director |
Biographies
| Name | Description |
|---|---|
Ted Karkus |
Mr. Ted William Karkus is Chairman of the Board, Chief Executive Officer of ProPhase Labs, Inc. He has been the Chairman of the Board and the Chief Executive Officer of the Company since June 2009. Mr. Karkus was formerly the managing member of Forrester Financial, LLC, a management consulting firm founded by Mr. Karkus in 2001. Forrester provided a wide range of services to emerging-growth companies, including the structuring and raising of working capital as well as assisting management in developing operational, marketing and financial strategies. Mr. Karkus was the primary investor in all portfolio company financings and had relationships with investment bankers, the media and a network of institutional investors and high net worth individuals. Mr. Karkus was instrumental in assisting the turn around of ID Biomedical, an influenza vaccine manufacturer, which in 2005 was sold to GalaxoSmithKline for over $1.4 billion. He provided financing, investment bankers, substantial sponsorship and advocated for the restructuring of management. Mr. Karkus has twenty-five years of experience in securities and capital markets including two years with Fahnestock & Co. Inc., a full-service brokerage firm, where he was Senior Vice President, Director of Institutional Equities and four years at S.G. Warburg, an investment bank, where he was an institutional equity salesman and developed a network of institutional investors. Mr. Karkus graduated with an MBA from Columbia University Graduate School of Business in 1984 where he received Beta Gamma Sigma honors. He graduated Magna Cum Laude from Tufts University in 1981. |
Robert Cuddihy |
Mr. Robert V. Cuddihy, Jr., is Executive Vice President, Chief Operating Officer, Chief Financial Officer of ProPhase Labs Inc. He has over twenty years of experience as the Chief Operating Officer and/or Chief Financial Officer of three public companies, including iDNA Inc., which focused on corporate communications, and HMG Worldwide Corporation, which focused on retail, planning and merchandising. Mr. Cuddihy has been the Chief Operating Office of the Company since July 2009 and the Chief Financial Officer of the Company since April 2011. He served as Chief Financial Officer and Treasurer of iDNA Inc. from September 2001 through February 2009 and Secretary from January 2003 through February 2009. From July 1987 to March 2001, Mr. Cuddihy was the Chief Financial Officer and Chief Operating Officer of HMG Worldwide Corporation, and also served as a director of such entity from February 1998 to May 2001. During 2009 and 2010, Mr. Cuddihy served as the President of Shannon Hill Associates, providing due diligence, financial structuring, operational analysis and transaction negotiation services for M&A, restructurings and divestitures. From July 1981 to July 1987, Mr. Cuddihy was with KPMG Peat Marwick, Certified Public Accountants, where he last served as a senior audit manager. Mr. Cuddihy graduated with a bachelors degree in accounting from Franklin and Marshall College in 1981. |
Mark Burnett |
Mr. Mark A. Burnett is Independent Director of ProPhase Labs, Inc. He currently serves as Chairman of Audit Committee and as a member of Compensation Committee. Mr. Burnett is the Executive Vice President and Chief Executive Officer for MercBloc, LLC, which he co-founded in 2007. MercBloc, LLC is a financial services administrator that has raised more than $500 million for investment from over 70 high net worth individuals. Mr. Burnett is also the managing member of Fuse Capital, LLC, which is a private securities trading and investment company. Since 1996, Mr. Burnett was in the business of building residential homes in the Nassau County region of Long Island, NY. For over 25 years, he also owned a seat on the New York Mercantile Exchange and started his career trading heating oil and crude oil futures contracts. He is still a member of NYMEX and currently holds memberships in the Chicago Climate Futures Exchange (C.C.F.E.) and the Intellectual Property Exchange International (I.P.X.I.). Mr. Burnett graduated with a double Bachelor of Arts from the State University of New York at Stony Brook in 1981. |
Mark Frank |
Mr. Mark Frank is Independent Director of ProPhase Labs, Inc. He currently serves as a member of Nominating Committee (as defined below) and Audit Committee, and as chairman of Compensation Committee. Mr. Frank is the President of a division of GSW Worldwide in Newtown, Pa. GSW is one of the health care advertising companies in the world with offices in thirteen markets. Mr. Frank has served as President since 2005 and was Executive Vice President before that. Mr. Frank has marketing, advertising and brand development experience in the areas of pharmaceuticals/biotechnology, medical device and diagnostics and health and wellness. GSW is a subsidiary of inVentiv Health, Inc., a corporation that was listed on NASDAQ until it was acquired in August 2010. InVentiv Health, Inc. provides a broad range of services to companies in the health care industry and its client roster is comprised of more than 350 pharmaceutical, biotech, life sciences and healthcare payor companies, including all top twenty global pharmaceutical manufacturers. Prior to his twelve years with GSW/inVentiv Health, he was a Director of Marketing for Novartis Pharmaceuticals, which develops and markets patent protected prescription drugs, the development and marketing of several brands in various therapeutic categories. Mr. Frank graduated with a BS degree in Exercise Science in 1983 and a MS degree in Public Health in 1990, both from the University of Massachusetts at Amherst. |
Louis Gleckel |
Dr. Louis Gleckel, M.D., is Independent Director of ProPhase Labs, Inc. He currently serves as a member of Nominating Committee (as defined below). Dr. Gleckel co-founded ProHealth Care Associates in 1997, a comprehensive state of the art multi-specialty physician group practice with offices in Long Island and Bronx, NY. At ProHealth, he is the Division Chief of Cardiology and Internal Medicine specializing in Preventative Cardiology, Metabolic Syndrome and Internal Medicine with particular emphasis on complications from high risk patients having Diabetes and Heart Disease. He was named to New York Magazine’s Doctors list for three years, New York Metro Area Doctors list for fourteen years and the 2008 Nassau County Doctors list. For over ten years Dr. Gleckel has been a team physician for the NY Jets and NY Islanders as well as for the tennis players at the US Open. Dr. Gleckel also served as Chairman of the Board of Invicta Corporation, a development stage company that designed, manufactured and marketed photochromic eyeglass lenses, for approximately four years until his resignation in February 2005. |
Mark Leventhal |
Mr. Mark Leventhal is Independent Director of ProPhase Labs, Inc. He currently serves as the Chairman of the Nominating Committee (as defined below) and as a member of Compensation Committee. In 1974, he joined The Beacon Companies, LLP, a business that developed office buildings, hotels, retail housing throughout the United States. Some of the projects in the Boston area included Rowes Wharf consisting of 100 luxury condos, 400,000 square feet of office space, a 230 room hotel, and a marina; One Post Office Square consisting of 750,000 sq. ft. of office space; three additional hotels (over 700 rooms) including the Meridian Hotel; over 2500 multifamily housing units in and around Boston; and One, Two and Three Center Plaza. Many of these properties formed the foundation for Beacon Properties, a REIT which went public with a $400 million valuation in 1994 and was listed on the New York Stock Exchange. Beacon Properties was subsequently sold to Equity Office Properties, an owner and operator of a national portfolio of office buildings, for approximately $4.4 billion in 1997. Since that time, Mr. Leventhal has continued to invest in real estate in Massachusetts, Rhode Island and Connecticut. Mr. Leventhal holds a Bachelor’s degree in Civil Engineering from Northeastern University. |
James McCubbin |
Mr. James McCubbin is Independent Director of ProPhase Labs, Inc. He currently serves as a member of Audit Committee. He is the Executive Vice President and Chief Financial Officer of WidePoint Corporation, a NYSE-AMEX listed corporation. He also serves on WidePoint’s Board of Directors and is its Secretary and Treasurer. WidePoint is a provider of Identity Access Management and Multi-Factor Authentication solutions offering advanced information technology through its innovative solutions to the government and commercial markets. Mr. McCubbin was promoted to Executive Vice President and Chief Financial Officer of WidePoint in May 2008. Prior to that time, from August 1998 till May 2008, Mr. McCubbin served as WidePoint’s Vice President and Chief Financial Officer. Prior to that time, from December 1997 to August 1998, Mr. McCubbin served as WidePoint’s Vice President, Controller, Assistant Secretary and Treasurer. Prior to the commencement of his employment with WidePoint in November 1997, Mr. McCubbin held various financial consulting, management, and/or staff positions with several companies in the financial and government sectors including but not limited to Memtec America Corporation, a continuous microfiltration water technology company, McBee Consulting, a healthcare consulting firm, Martin Marietta, presently known as Lockheed Martin, a multinational aerospace manufacturer and advanced technology company, and Ernst and Young, an international auditing and accounting firm. Mr. McCubbin presently serves on the Board of Directors of Tianjin Pharmaceutical Company, a NYSE-AMEX listed company. Mr. McCubbin was on the Board of Directors of Redmile Entertainment, a worldwide developer and publisher of interactive entertainment software, and served as its Audit Committee Chairman until his resignation on March 1, 2008. Mr. McCubbin is a graduate of the University of Maryland with a Bachelor of Science Degree in Finance and a Masters Degree in International Management. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Ted Karkus |
900,752 |
Robert Cuddihy |
444,327 |
Mark Burnett |
-- |
Mark Frank |
-- |
Louis Gleckel |
-- |
Mark Leventhal |
-- |
James McCubbin |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Ted Karkus |
0 | 0 |
Robert Cuddihy |
0 | 0 |
Mark Burnett |
0 | 0 |
Mark Frank |
0 | 0 |
Louis Gleckel |
0 | 0 |
Mark Leventhal |
0 | 0 |
James McCubbin |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
LEVENTHAL MARK S |
1,304 | $1.60 |
LEVENTHAL MARK S |
8,696 | $1.60 |
MCCUBBIN JAMES T |
834 | $1.55 |
LEVENTHAL MARK S |
102,700 | $1.60 |
LEVENTHAL MARK S |
47,300 | $1.42 |
KARKUS TED WILLIAM |
103,402 | $1.05 |
KARKUS TED WILLIAM |
141,388 | $0.98 |
CUDDIHY ROBERT V JR |
10,757 | $0.00 |
KARKUS TED WILLIAM |
134,409 | $0.00 |
CUDDIHY ROBERT V JR |
33,603 | $0.00 |
KARKUS TED WILLIAM |
19,192 | $0.90 |
KARKUS TED WILLIAM |
171,018 | $0.85 |
BURNETT MARK A |
100,000 | $0.87 |
CUDDIHY ROBERT V JR |
15,665 | $0.00 |
MCCUBBIN JAMES T |
5,640 | $0.00 |
BURNETT MARK A |
11,280 | $0.00 |
LEVENTHAL MARK S |
11,280 | $0.00 |
GLECKEL LOUIS |
11,280 | $0.00 |
FRANK MARK SHAWN |
11,280 | $0.00 |
BURNETT MARK A |
100 | $0.85 |
GLECKEL LOUIS |
10,925 | $0.00 |
MCCUBBIN JAMES T |
5,460 | $0.00 |
FRANK MARK SHAWN |
10,925 | $0.00 |
CUDDIHY ROBERT V JR |
15,170 | $0.00 |
BURNETT MARK A |
10,925 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
